RT Journal Article
SR Electronic
T1 Confirmation of HLA-II associations with TB susceptibility in admixed African samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.30.24308060
DO 10.1101/2024.05.30.24308060
A1 Croock, Dayna
A1 Swart, Yolandi
A1 Schurz, Haiko
A1 Petersen, Desiree C.
A1 Möller, Marlo
A1 Uren, Caitlin
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2024.05.30.24308060.abstract
AB The International Tuberculosis Host Genetics Consortium (ITHGC) demonstrated the power of large-scale GWAS analysis across diverse ancestries in identifying tuberculosis (TB) susceptibility loci. Despite identifying a significant genetic correlate in the human leukocyte antigen (HLA)-II region, this association did not replicate in the African ancestry-specific analysis, due to small sample size and the inclusion of admixed samples. Our study aimed to build upon the findings from the ITHGC and identify TB susceptibility loci in an admixed South African cohort using the local ancestry allelic adjusted association (LAAA) model. We identified a near-genome-wide significant association (rs3117230, p-value = 5.292 ×10−6, OR = 0.437, SE = 0.182) in the HLA-DPB1 gene originating from KhoeSan ancestry. These findings extend the work of the ITHGC, underscore the need for innovative strategies in studying complex admixed populations, and confirm the role of the HLA-II region in TB susceptibility in admixed South African samples. [148/150 words]Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the support of the DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research (SAMRC CTR), Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. We also acknowledge the Centre for High Performance Computing (CHPC), South Africa, for providing computational resources. This research was partially funded by the South African government through the SAMRC and the Harry Crossley Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by the Health Research Ethics Committee (HREC) of Stellenbosch University, South Africa (project number S22/02/031).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll genetic data used are retrospective datasets and are available through the cited articles.